BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

Several other research analysts have also commented on the company. BidaskClub raised BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Zacks Investment Research lowered BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Noble Financial reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. HC Wainwright reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 8th. Finally, Needham & Company LLC reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Friday, May 19th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $8.00.

Shares of BioCryst Pharmaceuticals (NASDAQ BCRX) opened at 5.00 on Friday. BioCryst Pharmaceuticals has a 52 week low of $3.75 and a 52 week high of $9.25. The firm’s market capitalization is $402.14 million. The firm’s 50-day moving average is $4.88 and its 200-day moving average is $6.13.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.02. BioCryst Pharmaceuticals had a negative return on equity of 276.62% and a negative net margin of 160.97%. The business had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $5.79 million. During the same period in the previous year, the firm posted ($0.22) EPS. The firm’s revenue for the quarter was down 35.4% compared to the same quarter last year. Equities analysts anticipate that BioCryst Pharmaceuticals will post ($0.74) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/03/biocryst-pharmaceuticals-inc-bcrx-downgraded-to-sell-at-valuengine.html.

A number of hedge funds have recently modified their holdings of BCRX. Wellington Management Group LLP purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter valued at about $1,700,000. Principal Financial Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 45 shares in the last quarter. Emory University purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter valued at about $3,153,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of BioCryst Pharmaceuticals during the first quarter valued at about $337,000. Finally, American International Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 45,230 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 2,989 shares in the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Stock Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.